Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [334]
News [1483]
Articles [66]
Editorials [3]
Conferences [72]
elearning [11]
What is required to advance data ethics, data sharing, and Open Science across...
Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India
What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )
20 Dec 2022
Access to Oncology Medicines Coalition - The Medicines Patent Pool
Charles Gore - Medicines Patent Pool, Geneva, Switzerland
Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )
1 Dec 2022
Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating...
Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan
Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma ( Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan )
26 Sep 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
A new era of early cancer detection with blood test may change cancer screening...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy
Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA
Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Lenvatinib remains standard of care for first-line therapy in advanced...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation